Loading
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
Michael Hofman is Professor of Nuclear Medicine and Director of the Prostate Cancer Theranostics and Imaging Centre of Excellence at the Peter MacCallum Cancer Centre in Melbourne. He led proPSMA, which proved that PSMA PET-CT beats conventional imaging for staging high-risk prostate cancer before curative-intent surgery or radiotherapy, and TheraP, the ANZUP trial that showed lutetium-177 PSMA-617 beats cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer. His publications include the proPSMA and TheraP reports, and his trials made Australia a global centre of theranostics. He now leads trials of earlier-line and combination radioligand therapy.
Shares proPSMA, ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, PSMA.
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, Lutetium-177 vipivotide tetraxetan, PSMA.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares A university cyclotron network with shared regulatory files for new tracers, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.
Shares proPSMA, ANZUP Cancer Trials Group, Prostate cancer.